Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
OLVG start met immunotherapie voor long- en niercelkanker
jul 2017 | Longoncologie, Uro-oncologie